Strategic Cooperation fueling the Global Monoclonal Antibodies Market

   As per our new research report “Global Monoclonal Antibody Market Analysis”, mergers and acquisitions and licensing agreements are quite active in the monoclonal antibodies market. With monoclonal antibodies available at all stages of development in the pipeline from discovery to phase III trials and continuing to win faster approval and greater revenue streams than more traditional pharmaceutical drugs, many companies around the globe has joined hands and forayed into this business.

   Our research indicates that large pharmaceutical companies are acquiring SME biotech companies having promising monoclonal antibodies in late-stage development. Additionally, large companies, such as Pfizer and Johnson & Johnson are encouraging collaboration agreements, with institutes and small biotech companies, to develop promising monoclonal antibodies. For instance, the acquisition by Roche of Genentech, for US$ 47 Billion in March 2009, signifies the importance of monoclonal antibodies within the industry. Pfizer’s acquisition of Wyeth for US$ 68 Billion was largely driven by its desire to obtain access to Wyeth’s monoclonal drugs, such as Enbrel, approved for rheumatoid arthritis.

   Besides, our report provides a thorough research and prudent analysis of the global monoclonal antibodies therapeutics market. The systematic and thorough research studies the global monoclonal antibodies therapeutics market to present an insight into its various segments, including Oncology, Autoimmune & Inflammatory Diseases, Respiratory Diseases, Neurological Diseases, and Cardiovascular Diseases. Further, the comprehensive analysis of the market at the regional level, points the United States as the current highest share-holder. However, future will see emerging countries, such as China & India posting significant growth rates.

   The report “Global Monoclonal Antibody Market Analysis” provides thorough research and rational analysis along with reliable statistics of the global monoclonal antibodies therapeutics industry. The report also provides extensive information on the traditional markets as well as on the emerging technologies. Besides, an insight of trends prevailing at the regional monoclonal therapeutics market segments across the globe along with analysis of key drugs has been covered in the report. Analysis and statistics regarding market size, growth, share, segmentation, and geographic distribution have been thoroughly studied in the report to present a comprehensive view of the market. The report has thoroughly examined market drivers; industrial developments, alliances & acquisitions, and competitive landscape to enable clients understand the market structure and its future progress.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM279.htm

Check DISCOUNTED REPORTS on: http://www.rncos.com/promotion.htm

About RNCOS:

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals study and analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the consultants in meeting their objectives in a cost-effective and timely manner.